Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a supplement make your flu shot last? new study investigates

NCT ID NCT07357467

Knowledge-focused Sponsor: Tsinghua University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This follow-up study checks if taking TUDCA or fatty acid supplements during a flu vaccine helps older adults (ages 60-70) keep their immunity longer. Researchers will measure antibody levels and immune cells about 8 months after vaccination. No new treatment is given—just one blood draw to see if the supplements boosted long-term protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TUDCA (Tauro Ursodesoxy Cholic Acid) and fatty acid supplements
What this could lead to
If successful, this study could show that taking TUDCA with a flu vaccine helps older adults stay protected longer, potentially improving vaccine strategies for seniors.
What could go wrong
This is a small, observational follow-up with only 30 participants. It does not test a new treatment, and results may not apply to the general population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This extended follow-up study includes participants from the original randomized controlled trial (Protocol ID: THU01-20240201; NCT06827873) conducted between February and April 2025. Thirty older adults (aged 60-70 years) were previously randomized to either the TUDCA group (n=15) or placebo group (n=15). All completed the 25-day intervention, received quadrivalent influenza vaccine on Day 3, and finished all Day 24 assessments. Participants were recruited from community health centers affiliated with the Second Affiliated Hospital of Bengbu Medical College, Anhui, China, and provided written informed consent for both the original and follow-up studies.

Ages

60 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Originally assigned to either the TUDCA supplementation group or placebo control group 2. No influenza vaccination or other vaccines received between April 2025 and December 2025 3. Willing to participate in this follow-up study and sign supplementary informed consent 4. Stable health condition Exclusion Criteria: 1. Started using immunosuppressants or hormonal medications after the original study 2. Experienced serious illness or hospitalization within the past month, or planning surgery soon 3. Experienced fever, cold, severe diarrhea, or taken influenza antiviral medications within the past month 4. Unable or unwilling to participate in blood collection 5. Lost to follow-up or unable to contact

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immunosenescence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immunosenescence Influenza

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tsinghua University

    Beijing, Beijing Municipality, 100084, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.